Trip Answers

Because clinicians ask questions

Search Clinical Questions

Searching TRIPanswers is fairly easy and currently basic (no Boolean etc), but this will evolve if there is a demand.

If you want to search for prostate cancer, simply type prostate cancer in the search box. If you want to search for prostate cancer screening, type prostate cancer screening.

We have envisaged users searching for their basic concept and then clicking on a relevant term in the tag cloud (if there are lots of results). In other words, the initial search gets you close to your Q&A while the tags allow you to refine your search to your topic of interest.

A total of 6322 clinical questions available

In a patient taking strontium for osteoporosis is their a link with memory loss and fits?

Associated tags: memory loss, Musculoskeletal disease, Neurology, osteoporosis, strontium ranelate

Question DetailsView Comments (0)

ANSWER

provided by TripAnswers

Moderate

Appraisal

Moderate

Confidence

Good

Click here for an explanation of these scores

Answer Rating key

	search		strong
	appraisal		weak
	confidence		moderate

Question answered:08/01/09

We looked on eMC for the Summary of Product Characteristics (SPC) information.

On the SPC [1] it says:

“In phase III studies, over 4 years, nervous system disorders were reported with higher frequency in patients treated with strontium ranelate, compared with placebo: disturbances in consciousness (2.5% vs. 2.0%), memory loss (2.4% vs. 1.9 %) and seizures (0.3% vs. 0.1%).”

We searched using TRIP, Medline and Cochrane for any more evidence about strontium ranelate and either memory loss or seizures, and found three reports:

A 2007 Health Technology Assessment report [2] states:

"Some nervous system disorders, including mental impairment, disturbed consciousness, memory loss and seizures, were also more common in patients randomised to strontium ranelate."

This report was similar to others mentioned in a 2008 Br J Clin Pharmacol article [3] and a Cochrane Review [4]. In the case of the Cochrane review they reported that in trials memory loss occured in 2.4% of patients on strontium ranelate compared to 1.9% assigned to the placebo intervention.

References

1. eMC. SPC for Protelos, text last revised Sept 04.(http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=15410)
2. http://www.ncbi.nlm.nih.gov/pubmed/17280622
3. http://www.ncbi.nlm.nih.gov/pubmed/18754840
4. http://www.ncbi.nlm.nih.gov/pubmed/16856092

DISCLAIMER: TRIPanswers is a collection of clinical questions and answers. Each provider will have their own methodology in answering questions and these are likely not to be as rigorous as systematic review. If you have any doubt as to the implications of this contact the Q&A Service Provider for further information. This document is presented for information purposes only. This document cannot and should not be used as a basis of diagnosis or choice of treatment, and is in no way intended to replace professional medical care or attention by a qualified practitioner. TRIPanswers and TRIP Database Ltd are not responsible or liable for, directly or indirectly, ANY form of damage whatsoever resulting from the use/misuse of information contained in or implied by this document. Also, ensure you have read the terms and conditions for using the site.

Need to search for more evidence?

Help us improve this answer

Leave comments or suggestions below

Email address: (in case we need to get back to you)

Name: (for display on the site)

Comments:

Enter the code shown in the image:

Disclaimer:

TRIP will review each comment and will only publish those we feel will enhance a particular answer. As a result of the review process there will be a delay between submission and publication of accepted comments.

Tag Cloud